Cargando…
What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection
The linchpin of precision medicine is molecular genetic and genomic testing. Molecular biomarkers are important for establishing precise diagnoses and for predicting therapeutic responses that enable cancer patients to receive personalized and targeted treatment. Below are highlights of the current...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Pathologists and the Korean Society for Cytopathology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601954/ https://www.ncbi.nlm.nih.gov/pubmed/34788978 http://dx.doi.org/10.4132/jptm.2021.09.01 |
_version_ | 1784601469184376832 |
---|---|
author | Chen, Guoli Tsang, Patricia C. |
author_facet | Chen, Guoli Tsang, Patricia C. |
author_sort | Chen, Guoli |
collection | PubMed |
description | The linchpin of precision medicine is molecular genetic and genomic testing. Molecular biomarkers are important for establishing precise diagnoses and for predicting therapeutic responses that enable cancer patients to receive personalized and targeted treatment. Below are highlights of the current considerations in next generation sequencing (NGS) panel selection, and in molecular testing of solid tumors of the lung, digestive system, thyroid and soft tissue. |
format | Online Article Text |
id | pubmed-8601954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Korean Society of Pathologists and the Korean Society for Cytopathology |
record_format | MEDLINE/PubMed |
spelling | pubmed-86019542021-12-01 What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection Chen, Guoli Tsang, Patricia C. J Pathol Transl Med Newsletter The linchpin of precision medicine is molecular genetic and genomic testing. Molecular biomarkers are important for establishing precise diagnoses and for predicting therapeutic responses that enable cancer patients to receive personalized and targeted treatment. Below are highlights of the current considerations in next generation sequencing (NGS) panel selection, and in molecular testing of solid tumors of the lung, digestive system, thyroid and soft tissue. The Korean Society of Pathologists and the Korean Society for Cytopathology 2021-11 2021-11-12 /pmc/articles/PMC8601954/ /pubmed/34788978 http://dx.doi.org/10.4132/jptm.2021.09.01 Text en © 2021 The Korean Society of Pathologists/The Korean Society for Cytopathology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Newsletter Chen, Guoli Tsang, Patricia C. What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection |
title | What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection |
title_full | What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection |
title_fullStr | What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection |
title_full_unstemmed | What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection |
title_short | What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection |
title_sort | what’s new in molecular genetic pathology 2021: solid tumors and ngs panel selection |
topic | Newsletter |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601954/ https://www.ncbi.nlm.nih.gov/pubmed/34788978 http://dx.doi.org/10.4132/jptm.2021.09.01 |
work_keys_str_mv | AT chenguoli whatsnewinmoleculargeneticpathology2021solidtumorsandngspanelselection AT tsangpatriciac whatsnewinmoleculargeneticpathology2021solidtumorsandngspanelselection |